"Study results suggest that OLFM4 LY6D and S100A7 immunoreactivity are associated with an aggressive phenotype of estrogen receptor (ER)-positive breast carcinoma and these are potent markers for distant metastasis of ER-positive breast cancer patients."xsd:string